Markets

Muscular dystrophy biotech aTyr Pharma files for a $86 million IPO

aTyr Pharma, which is developing restorative protein therapeutics for rare muscular dystrophies, filed on Monday with the SEC to raise up to $86 million in an initial public offering.

aTyr notes that September 2013 biotech Acceleron Pharma (XLRN; +128%) is developing a protein therapeutic designed to increase muscle mass in patients with neuromuscular disorders.

The San Diego, CA-based company, which was founded in 2005, plans to list on the NASDAQ under the symbol LIFE. aTyr Pharma initially filed confidentially on December 22, 2014. J.P. Morgan and Citi are the joint bookrunners on the deal. No pricing terms were disclosed.

The article Muscular dystrophy biotech aTyr Pharma files for a $86 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

XLRN

Other Topics

IPOs

Latest Markets Videos

    Renaissance Capital

    Renaissance Capital is the global leader in providing pre-IPO institutional research and management of IPO-focused investment products.

    Learn More